Trestle Biotherapeutics
A preclinical-stage biotechnology company developing implantable, bioengineered kidney tissues to eliminate the need for dialysis and traditional organ transplants.
- CEO / Founder
- Ben Shepherd
- Team Size
- 11-50
- Stage
- Preclinical; currently engaged in IND-enabling research and a 2025 strategic collaboration with Humacyte to develop vascularized organ prototypes.
- Total Funding
- $1,200,000+
- Latest Round
- Wellcome Leap HOPE Program Award (Mar 2024)
- Key Investors
- ["Y Combinator","Acequia Capital","Black Mountain Ventures","KidneyX","Wellcome Leap"]
Technology & Products
Key Products
["Bioengineered Implantable Kidney Tissue","Vascularized Kidney Organoids","Stem cell-derived Ureteric Bud and Nephron Progenitor Platform","3D Biofabricated Renal Tissue Models"]
Technological Advantage
Holds exclusive licenses to foundational bioprinting and stem cell technologies from Harvard's Wyss Institute and Kumamoto University, enabling the production of complex renal structures at commercial scale.
Market & Competition
Target Customers
Patients with end-stage renal disease (ESRD), nephrology clinics, healthcare systems, and organ transplant centers.
Industry Verticals
["Biotechnology","Regenerative Medicine","Nephrology","Healthcare"]
Competitors
["eGenesis","Miromatrix Medical (United Therapeutics)","IVIVA Medical","Organovo"]